The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.